Ginkgo Bioworks Holdings, Inc. 8-K Filing
Ticker: DNABW · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1830214
| Field | Detail |
|---|---|
| Company | Ginkgo Bioworks Holdings, Inc. (DNABW) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ginkgo Bioworks Holdings, Inc. (ticker: DNABW) to the SEC on Dec 23, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (stered Class A common stock, par value $0.0001 per share DNA NYSE Indicate by check).
How long is this filing?
Ginkgo Bioworks Holdings, Inc.'s 8-K filing is 2 pages with approximately 629 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 629 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-23 17:26:04
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share DNA NYSE Indicate by check
Filing Documents
- dna-20251218.htm (8-K) — 23KB
- 0001628280-25-058791.txt ( ) — 139KB
- dna-20251218.xsd (EX-101.SCH) — 2KB
- dna-20251218_lab.xml (EX-101.LAB) — 22KB
- dna-20251218_pre.xml (EX-101.PRE) — 13KB
- dna-20251218_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. Jennifer Wipf, who was previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will assume responsibilities related to the Company's operations, including day-to-day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. Ms. Wipf previously led the Company's commercial function, where she played a key role in growing the company's cell engineering business. Before joining the Company, Ms. Wipf spent more than a decade at Merck & Co., gaining extensive experience in vaccine development, domestic and international plant management, and U.S. market commercial operations. Ms. Wipf holds an M.S. in Chemical Engineering from Stanford University and a B.S. in Bioengineering from the University of Arizona.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: December 23, 2025 By: /s/ Karen Tepichin Name: Karen Tepichin Title: General Counsel